Garaventa A, Guerra P, Arrighini A, Bertolazzi L, Bestagno M, De Bernardi B, Lanino E, Villavecchia G P, Claudiani F
Department of Pediatric Hematology-Oncology, Giannina Gaslini Children's Hospital, Genova, Italy.
Cancer. 1991 Feb 15;67(4):922-8. doi: 10.1002/1097-0142(19910215)67:4<922::aid-cncr2820670411>3.0.co;2-d.
From February 1986 to December 1988, 31 children with advanced pretreated neuroblastoma were treated with 131-I meta-Iodobenzylguanidine (131-MIBG). Thirteen children had been resistant to first-line therapy, three had suffered a local relapse, and fourteen had suffered a disseminated relapse without over bone marrow infiltration. One child was treated initially because of resistance to first-line therapy, and subsequently for a local relapse. A total of 72 courses of 131-MIBG was administered, with doses ranging from 2.8 to 6.0 GBq (median, 3.7 GBq). One child received five courses, two four courses, 13 three courses, four two courses, and 12 one course of 131-MIBG. The most common toxic effect was thrombocytopenia, with a platelet level of less than 50,000/cmm occurring after 19 of 60 evaluable courses. A leukocyte count less than 1000/cmm was seen only once. There were six major responses (two complete) lasting 4 to 9 months, and two minor responses lasting longer than 38 and 44 months. Responses were seen more commonly in children whose only lesion was a residual primary tumor and in children who had not been pretreated who experienced disseminated relapse. Further studies of the role of 131-I meta-Iodobenzylguanidine in treatment of neuroblastoma are needed.
1986年2月至1988年12月，31例晚期经预处理的神经母细胞瘤患儿接受了131碘间碘苄胍（131-MIBG）治疗。13例患儿对一线治疗耐药，3例局部复发，14例发生播散性复发但无骨髓浸润。1例患儿最初因对一线治疗耐药而接受治疗，随后因局部复发接受治疗。共给予72个疗程的131-MIBG，剂量范围为2.8至6.0 GBq（中位数为3.7 GBq）。1例患儿接受了5个疗程，2例接受了4个疗程，13例接受了3个疗程，4例接受了2个疗程，12例接受了1个疗程的131-MIBG。最常见的毒性作用是血小板减少，60个可评估疗程中有19个疗程后血小板水平低于50,000/cmm。白细胞计数低于1000/cmm仅出现过一次。有6例主要缓解（2例完全缓解），持续4至9个月，2例轻微缓解，持续时间超过38个月和44个月。在仅残留原发性肿瘤为唯一病变的患儿以及未接受过预处理而发生播散性复发的患儿中，缓解更为常见。需要进一步研究131碘间碘苄胍在神经母细胞瘤治疗中的作用。
